drugset / Trial / NCT00366041

Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

NCT00366041 ↗

RandomizedSingle-groupSingle-blindTreatment

Summary

After severe burn injury, the full-thickness burn areas are excised (in the first week) and then temporarily covered with allograft (cryogenic preserved cadaver skin). This first covering is then replaced with thin skin meshed autograft. In this study, either the dermal substrates cellularised LG002 or uncellularised LG002 will be grafted, after excision, in symmetrical areas, in replacement of the allografts. Fourteen to twenty one days after this first covering, the dermal substrate will be covered with thin skin meshed autograft.

Timeline

Start
2006-02
Primary completion
2008-12
Completion
2009-12

Outcome

Outcome not reported

Stopped: “not appropriate to carry on the study”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LG002 Vaccine — —

Indications

No indication recorded.